00241 ALI HEALTH
- 3.060
- +0.110+3.73%
ALI HEALTH News
CCB International: Maintaining Ali Health's (00241) “Outperform Market” Rating Target Price by 33% to HK$4.2
CCB International cut Ali Health's (00241) revenue forecast for 2024 by 16.4%.
Big Bank Rating | Dahua Jixian: Lowering Ali Health's Target Price to HK$4 to Maintain “Buy” Rating
Dahua Jixian published a report. Alibaba Health's revenue for the 2024 fiscal year is expected to drop 5% year-on-year, adjusted profit will increase by 30% year-on-year, and the revenue and profit targets for fiscal year 2025 are 15% and 70% year-on-year growth, respectively. As business expansion was slower than expected, the bank lowered Ali Health's revenue growth forecast for the 2024 and 2025 fiscal years from 14% and 21% to -5% and 15%, respectively, but with the synergy between steady demand for healthcare products and Ali Mama's marketing business, it remains optimistic about its long-term growth prospects. Dahua Jixian maintains Ali Health's “buy” rating, and the target price was lowered from HK$6 to HK$4
Lyon: Maintaining Ali Health's (00241) “Buy” Rating Target Price Reduced to HK$4.1
The Zhitong Finance App learned that Lyon released a research report stating that the target price for Ali Health (00241) was lowered from HK$5.6 to HK$4.1, maintaining the “buy” rating. The bank expects Alibaba Health to face a higher base effect than expected in the second half of fiscal year 2024. Revenue is expected to fall 19% year on year, and adjusted net profit is expected to drop 12% year on year. It also pointed out that Alibaba Health's business growth should be normalized in February of this year. Revenue and adjusted net profit for fiscal year 2025 are expected to increase by more than 16% and 70% respectively, benefiting from Ali Mama's advertising platform sharing advertising revenue.
Changes in Hong Kong stocks | Alibaba Health (00241) fell more than 4%, institutions say online drug sales are slowing down in the long term or facing challenges
Ali Health (00241) fell by more than 4%. As of press release, it was down 4.23% to HK$2.94, with a turnover of HK$98.481,600.
Dragon (01930) will pay a final dividend of HK$0.00241 per share on July 26
Qilong (01930) announced that the company will pay a final dividend of 0.00 per share on July 26, 2024...
Ali Health (00241.HK) grants a total of 1.93 million restricted share units
Gelonghui March 15 | Ali Health (00241.HK) issued an announcement. On March 15, 2024, the company granted a total of 1.93 million restricted share units to 12 grantees in accordance with the terms of the share award plan. The purpose of granting restricted share units is: (i) to provide skilled and experienced persons with an opportunity to acquire shares in the company in order to absorb them to promote the further development and expansion of the Group; (ii) recognize the contributions of the Group's current employees to the Group's success and development; and/or (iii) comprehensively motivate and encourage employees to remain in the Group to promote future development and expansion.
Alibaba Health Shareholders to Vote March 26 on Contract Renewal With Affiliates
Shareholders of Alibaba Health Information Technology (HKG:0241) will meet March 26 to vote on the proposed renewal of two agreements with affiliates of the company, a filing posted on the Hong Kong b
Jiudian Pharmaceutical (300705.SZ): E-commerce companies mainly sell on Jingdong Pharmacy, Ali Health and the company's own applets
Gelonghui, Feb. 22丨Jiudian Pharmaceutical (300705.SZ) said during a survey of specific subjects that e-commerce companies mainly sell on Jingdong Pharmacy, Ali Health and the company's own mini-programs. Both channels have achieved good growth.
Ali Health [00241] now reports HK$3.06, a decrease of 5.26%
As of 09:53, Ali Health [00241] reported HK$3.06, down 0.17 HK$5.26% from yesterday's closing price of HK$3.23, with a turnover of HK$133.39 million. Today's high price was HK$3.23, and the lowest price was HK$3.06. Based on yesterday's closing price, the 10-day average price was HK$3.02, and the 50-day average price was HK$3.76. The current price-earnings ratio was 71.46 times, and the 14-day strength and weakness index was 52.08.
Hong Kong Shares Fall in Likely Technical Correction -- Market Talk
0821 GMT - Hong Kong's Hang Seng Index fell 0.3% to close at 16081.89, reversing earlier gains in a likely technical correction. Electronics and technology companies led losers. Semiconductor Manufact
Healthcare concept generally rises, Pharmaco-Ming Kangde (02359) rises 9.80% Health Insurance Administration opinion draft encourages high-quality drug innovation and development, and many pharmaceutical companies to buy back shares
Jinwu Financial News | Healthcare concepts are rising. As of press release, Lai Kai Pharmaceutical (02105) rose 10.02%, Pharmaceutical Kangde (02359) rose 9.80%, Pharmaceutical Biotech (02269) rose 9.47%, Cinda Biotech (01801) rose 8.79%, and Ali Health (00241) rose 7.26%. The National Health Insurance Administration's “Notice on Establishing a Initial Price Formation Mechanism for Newly Launched Chemical Drugs to Encourage High Quality Innovation” solicited comments through relevant industry associations. Among them, “The higher the self-evaluation score, the higher the innovative value content of the drug, and the initial price of the newly launched drug
Changes in Hong Kong stocks | Alibaba Health (00241) rose more than 8% in 2 trading days and 16% recently completed the acquisition of Ali Mama's exclusive management rights in the healthcare category
Ali Health (00241) rose more than 8% and rose 16% in 2 trading days. As of press release, it had risen 8.25% to HK$3.28, with a turnover of HK$71.01 million.
Ali Health [00241] now reports HK$3.19, an increase of 5.28%
As of 09:30 Alibaba Health [00241] reported HK$3.19, up HK$3.16 or 5.28% from yesterday's closing price, with a turnover of HK$4.8495 million. Today's high price was HK$3.19 and the lowest price was HK$3.1. Based on yesterday's closing price, the 10-day average price was HK$3.03, and the 50-day average price was HK$3.82. The current price-earnings ratio was 67.04 times, and the 14-day strong and weak index was reported at 43.51.
Alibaba Health to Renew Marketing, Technical Services Deals With Affiliates
Alibaba Health Information Technology (HKG:0241) intends to continue procuring marketing services from affiliate Hangzhou Alimama Software Services and technical services from associate Taobao China H
Alibaba Health Acquires Parent's Tmall Healthcare Marketing Services
Alibaba Health Information Technology (HKG:0241) has completed the acquisition of the exclusive marketing rights for the healthcare category on Alibaba Group's (HKG:9988) e-commerce platform Tmall. Th
Ali Health (00241) issues 14,500 shares under the share award program
Ali Health (00241) announced that on January 15, 2024, the company exercised shares in the company due to its employees...
Ali Health (00241) completed the acquisition of Alibaba Mama's exclusive management rights in the healthcare category through the issuance of shares in consideration
Zhitong Finance App News, Alibaba Health (00241) announced that on November 28, 2023, the company entered into a share purchase agreement with the seller (Taobao Holdings Co., Ltd., a direct wholly-owned subsidiary of Alibaba Holdings). The company agreed to purchase all of the target company's issued share capital, subject to the terms and conditions of the share purchase agreement. The consideration payable by the company to the seller at the time of delivery is HK$13.512 billion, which will be paid as follows: the company issues 2,558 billion shares of consideration to the seller (and/or its representative) at an issue price of HK$4.50 per share at the time of delivery; and the company now at the time of delivery
CITIC Securities: Looking at investment risks and opportunities in 2024 from the trend of Chinese and US technology stocks in the past 10 years
The AI concept drives the performance of Chinese and US technology stocks to significantly outperform the domestic market in 2023, with US tech giants leading the world.
Chinese Tech, Advanced Manufacturing Stocks Remain Favorable
0311 GMT - Chinese technology and advanced manufacturing stocks remain favorable this year, Saxo Markets chief China strategist Redmond Wong says. China's recent key economy conferences indicate the c
China's CPI, PPI Likely Fell in December
0301 GMT - China's producer-price index likely fell 2.6% on year in December, while consumer prices likely declined 0.6% after slipping in October and November, Moody's Analytics says in its weekly As
Analysis
Price Target
No Data
